GTBP News and Press, GT Biopharma Inc. From 03/17/21

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results Up to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance No Progenitor-derived or Autologous/Allogenic Cell...

Penny Stocks To Watch For March 2021 If You Like The Biotech Sector As we approach the third week of March, penny stocks seem to be on a hot streak. This is a combination of the massive decline in covid cases and the $1.9 trillion stimulus package passing. Also, investors’ fear a...

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference PR Newswire BEVERLY HILLS, Calif. , March 10, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercializatio...

Gainers: Auris Medical (EARS) +73%, AnPac Bio-Medical Science ANPC +51%, Second Sight Medical Products (EYES) +29%, Sintx Technologies (SINT) +27%, GT Biopharma (GTBP) +25%.Losers: ACADIA Pharmaceuticals ACAD -48%, Graybug Vision GRA...

Biotech Penny Stocks To Watch Right Now While penny stocks are well-known for volatility, so too are certain sectors. Possibly no other sector has continued its volatile trend throughout history better than biotechnology. With things like tech stocks, of course, R&D plays a role, an...

AnPac Bio-Medical Science (ANPC) +75% after update on cancer detection system CDAPS.Second Sight Medical Products (EYES) +67%.GT Biopharma (GTBP) +45%.Auris Medical Holding Ltd. (EARS) +24%.Taoping Inc. (TAOP) +10% on launching Blockchain Business Division.AirNet Technology (ANTE) +...

Are These Biotech Penny Stocks On Your Watch List Right Now? The tech wreck continues this week, but that hasn’t put a pause on other sectors. Furthermore, the market’s appetite for risk appears to be growing stronger once again. Earlier today, we saw the list of Reddit ...

GT Biopharma (GTBP) announces preclinical results for its ROR1 TriKE product candidate as a prospective therapy for the treatment of prostate cancer.The ROR1 TriKE was evaluated in several preclinical models of prostate cancer, and was found to be effective at promoting NK cell killing o...

GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer PR Newswire BEVERLY HILLS, Calif. , March 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on dis...

GT Biopharma (GTBP) announces the addition of the University of Wisconsin's Madison Carbone Cancer Center as a new clinical trial site for its ongoing GTB-3550 TriKE multicenter Phase I/II trial, testing the treatment in certain patients with acute myeloid leukemia ((AML)).GTB-...